Early Dynamic PET/CT and 18F-FDG Blood Flow Imaging in Bladder Cancer Detection

Belakhlef, Sam; Church, Clifford; Jani, Chirag; Lakhanpal, Suresh

doi:10.1097/rlu.0b013e3182443110

Cited by 22 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an effort to improve tumor conspicuity through an increase of tumor-to-urine SUVmax ratio, few authors have investigated the utility of early dynamic acquisitions, before radioactive urine has had a chance to fill the bladder (13,67,68). In these proof-of-concept studies, the authors suggested that such dynamic acquisitions might improve tumor detection and staging; however, the impact on LN staging was not evaluated.…”

Section: Early Dynamic Acquisitionsmentioning

confidence: 99%

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) is the 10th most common cancer worldwide. Approximately one quarter of patients with BC have muscle-invasive disease (MIBC). Muscle-invasive disease carries a poor prognosis and choosing the optimal treatment option is critical to improve patients’ outcomes. Ongoing research supports the role of 2-deoxy-2-(18F)fluoro- D -glucose positron emission tomography (18F-FDG PET) in guiding patient-specific management decisions throughout the course of MIBC. As an imaging modality, 18F-FDG PET is acquired simultaneously with either computed tomography (CT) or MRI to offer a hybrid approach combining anatomical and metabolic information that complement each other. At initial staging, 18F-FDG PET/CT enhances the detection of extravesical disease, particularly in patients classified as oligometastatic by conventional imaging. 18F-FDG PET/CT has value in monitoring response to neoadjuvant and systemic chemotherapy, as well as in localizing relapse after treatment. In the new era of immunotherapy, 18F-FDG PET/CT may also be useful to monitor treatment efficacy as well as to detect immune-related adverse events. With the advent of artificial intelligence techniques such as radiomics and deep learning, these hybrid medical images can be mined for quantitative data, providing incremental value over current standard-of-care clinical and biological data. This approach has the potential to produce a major paradigm shift toward data-driven precision medicine with the ultimate goal of personalized medicine. In this review, we highlight current literature reporting the role of 18F-FDG PET in supporting personalized management decisions for patients with MIBC. Specific topics reviewed include the incremental value of 18F-FDG PET in prognostication, pre-operative planning, response assessment, prediction of recurrence, and diagnosing drug toxicity.

show abstract

Section: Early Dynamic Acquisitionsmentioning

confidence: 99%

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, this protocol intrinsically contains a masking effect of the tracer in the urine and renal parenchyma. Technical developments in FDG-PET/ CT with early dynamic (ED) scans have enabled the estimation of tumour blood flow in hepatocellular carcinoma [10,11], pancreatic cancer [12] and bladder cancer [13]. The ability to estimate tumour blood flow and metabolic activity from a single FDG-PET/CT study may enhance the ability to detect and characterize RCC tumours.…”

Section: Introductionmentioning

confidence: 99%

Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This technique was noninvasive and could improve the detection of locally recurrent or residual bladder tumors; however, furosemide must be injected at least 2 hours after radiotracer injection, and many delayed images must be taken (6). In addition, early dynamic FDG PET images can demonstrate the presence of bladder lesions that are obscured by urine activity on routine images taken 1 hour after a radiotracer is injected (13).…”

Section: Discussionmentioning

confidence: 99%

A New Method for Detecting Urinary Bladder Cancer by Using FDG PET/CT

Chen

Yeh

Su³

et al. 2014

Technol Cancer Res Treat

View full text Add to dashboard Cite

To evaluate the accuracy of a new fluorine-18-2-fluoro-2-deoxy-d-glucose ((18)F-FDG) positron emission tomography (PET)/computed tomography (CT) method when applying an increased upper limit of the image threshold (IULIT) to detect bladder cancer. All patients with an unknown history of bladder tumors were retrospectively included for analysis. Applying an IULIT in PET showed a hypermetabolic focus. (18)F-FDG accumulation in the bladder that was higher or lower than the urinary level of (18)F-FDG was considered an abnormal focus. In 12 of the 28,767 patients with bladder cancer, applying an IULIT in PET allowed the visualization of the contrast between lesion and urinary activity. The proposed method could increase the accuracy of detection of bladder cancer.

show abstract

Early Dynamic PET/CT and 18F-FDG Blood Flow Imaging in Bladder Cancer Detection

Abstract: Early dynamic FDG PET images can demonstrate bladder lesions that are obscured by urine activity on routine images at 1 hour.

Cited by 22 publications

References 9 publications

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

The Role of 18F-FDG PET/CT in Guiding Precision Medicine for Invasive Bladder Carcinoma

Clinical role of early dynamic FDG-PET/CT for the evaluation of renal cell carcinoma

A New Method for Detecting Urinary Bladder Cancer by Using FDG PET/CT

Contact Info

Product

Resources

About